After cutting its 2016 earnings guidance twice already this year, Valeant Pharmaceuticals is expected to once again lower its earnings forecast on next week’s much-anticipated earnings call, analysts with Morgan Stanley said in a Tuesday investment note.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
